GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (NAS:EGRX) » Definitions » Cyclically Adjusted PS Ratio

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Cyclically Adjusted PS Ratio : 0.33 (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-05-16), Eagle Pharmaceuticals's current share price is $4.61. Eagle Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 was $14.17. Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 0.33.

The historical rank and industry rank for Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

EGRX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.29   Med: 1.51   Max: 3.81
Current: 0.33

During the past years, Eagle Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 3.81. The lowest was 0.29. And the median was 1.51.

EGRX's Cyclically Adjusted PS Ratio is ranked better than
90.63% of 747 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs EGRX: 0.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eagle Pharmaceuticals's adjusted revenue per share data for the three months ended in Jun. 2023 was $4.914. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $14.17 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eagle Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2.26

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 2.12 2.26 2.09 1.37

Competitive Comparison of Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Eagle Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=4.61/14.17
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eagle Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Eagle Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=4.914/128.7287*128.7287
=4.914

Current CPI (Jun. 2023) = 128.7287.

Eagle Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201309 0.439 98.790 0.572
201312 0.395 98.326 0.517
201403 0.565 99.695 0.730
201406 0.413 100.560 0.529
201409 0.200 100.428 0.256
201412 0.399 99.070 0.518
201503 2.414 99.621 3.119
201506 0.386 100.684 0.494
201509 0.368 100.392 0.472
201512 1.092 99.792 1.409
201603 1.892 100.470 2.424
201606 2.485 101.688 3.146
201609 2.300 101.861 2.907
201612 4.999 101.863 6.317
201703 4.751 102.862 5.946
201706 3.112 103.349 3.876
201709 3.998 104.136 4.942
201712 3.001 104.011 3.714
201803 3.012 105.290 3.683
201806 3.839 106.317 4.648
201809 3.316 106.507 4.008
201812 3.822 105.998 4.642
201903 3.453 107.251 4.145
201906 4.005 108.070 4.771
201909 3.010 108.329 3.577
201912 3.420 108.420 4.061
202003 3.367 108.902 3.980
202006 3.069 108.767 3.632
202009 3.621 109.815 4.245
202012 3.744 109.897 4.386
202103 3.156 111.754 3.635
202106 3.629 114.631 4.075
202109 3.048 115.734 3.390
202112 3.282 117.630 3.592
202203 8.978 121.301 9.528
202206 5.776 125.017 5.947
202209 5.005 125.227 5.145
202212 4.631 125.222 4.761
202303 5.041 127.348 5.096
202306 4.914 128.729 4.914

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eagle Pharmaceuticals  (NAS:EGRX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eagle Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eagle Pharmaceuticals (Eagle Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Executives
Scott Tarriff director, officer: President and CEO 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Richard A. Edlin director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Michael Shawn Moran officer: EVP, Chief Commercial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Brian Joseph Cahill officer: Chief Financial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Judith Ng-cashin officer: Chief Medical Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Hudson Executive Capital Lp director C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281
Hec Management Gp Llc director 1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Douglas L Braunstein director HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Sander A Flaum director 630 PARK AVE, NEW YORK NY 10019
Pete A. Meyers officer: Chief Financial Officer C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355
David Pernock director 405 EAGLEVIEW BOULEVARD, EXTON PA 19341
Proquest Investments Iv, L.p. 10 percent owner 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Steven L. Krill officer: Chief Scientific Officer C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Headlines

From GuruFocus